title: [Chemotherapy of cerebral metastasis of lung cancer].
abstract: Between November 1983 and November 1988, 60 patients with cerebral metastases arising from primary lung cancer were treated with chemotherapy. Thirty patients received a 5-day course of cisplatin (total dose: 200 mg/sq.m). The remaining 30 patients received VP 16 in doses of 250 mg/sq.m. administered 12-hourly by intravenous infusion over one hour (total dose: 1,500 mg/sq.m.). Twenty-seven percent of the patients who received cisplatin showed objective responses as assessed by computerized tomography; 10% had serious toxic reactions. Thirty percent of the patients who received VP 16 showed objective responses, but 43% had severe bone marrow aplasia resulting in a 33% death rate due to infection. The median survival of responders was 8 months in both treatment groups. The objective response rates as assessed by histology were 33% in patients with oat-cell carcinoma and 27% in patients with other histological types. VP 16 must be abandoned, being too toxic in high doses. High-dose cisplatin can be used in the treatment of cerebral metastases of lung cancer, side by side with radiotherapy.
authors.affiliation: Département des Maladies respiratoires, Hôpital Sainte-Marguerite, Marseille.
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Herkert
authors.forename: F
authors.initials: F
authors.lastname: Soyez
authors.forename: J P
authors.initials: JP
authors.lastname: Kleisbauer
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D005047:Etoposide; D002945:Cisplatin
vernacular_title: Chimiothérapie des métastases cérébrales des cancers bronchiques.